In our latest Newsletter, we share the story behind our investment in C-HAS+, a biotech venture originating from Kumamoto University. The company is pioneering a world-first system using C. elegans to assess the impact of food and pharmaceutical ingredients on healthy lifespan.
Beyond its scientific innovation, C-HAS+ embodies our Investment Theme 4: creating jobs and vibrant communities in regional Japan. By offering young researchers and women, career opportunities in Kumamoto, the company is contributing not only to wellness innovation but also to the strengthening of social capital.
Read the full article here: Why we invested in C-HAS+ (SIIFIC Substack)
